Uladzislau/AdobeStockNeurocrine Biosciences today announced new data from a post-hoc analysis of the phase 4 KINECT-PRO open-label study that confirms robust rates of symptomatic remission of tardive dyskinesia (TD) were achieved with once-daily valbenazine (Ingrezza) capsules. The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission. This post-hoc analysis demonstrated high rates of symptomatic remission and associated improvements in PROs, including physical and socioemotional impacts of TD. Neurocrine Biosciences presents new post-hoc analysis: treatment with Ingrezza® (valbenazine) capsules achieves earlier remission of tardive dyskinesia symptoms while reducing patient-reported disease burden. Kuntz L. New Ingrezza data demonstrates functional and quality of life improvements in patients with tardive dyskinesia.